MDT · Insider Trading
Medtronic plc
Every open-market purchase and sale reported by MDT officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Form 4 Filings
50
most recent
Open-Market Buys
1
code P
Sales
5
code S
Reporting Insiders
25
current holders
MDT — Recent Form 4 Transactions (latest 2026-09-17)
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-17 | Harry Skip Kiil | EVP & President Cardiovascular | Sell | −1,483 | −$138.88K |
| 2026-09-16 | Denise L. Blomquist | Chief Accounting Officer | G | −600 | — |
| 2026-08-24 | Michael Marinaro | EVP, Pres MedSurg and Americas | F | −1,084 | −$100.05K |
| 2026-08-04 | Thierry Pieton | EVP & Chief Financial Officer | A | +11,537 | — |
| 2026-08-04 | Denise L. Blomquist | Chief Accounting Officer | MIXED | +2,125 | −$18.10K |
| 2026-08-04 | Kweli Thompson | EVP & President, Neuroscience | MIXED | +5,184 | −$148.49K |
| 2026-08-04 | Geoffrey Martha | Chairman and CEO | MIXED | +25,723 | −$1.35M |
| 2026-08-04 | Harry Skip Kiil | EVP & President Cardiovascular | MIXED | +6,156 | −$262.49K |
| 2026-08-04 | Michelle Quinn | EVP, GC and Secretary | A | +6,346 | — |
| 2026-08-04 | Michael Marinaro | EVP, Pres MedSurg and Americas | MIXED | +53,751 | −$286.57K |
| 2026-08-04 | Matthew R. Walter | SVP, Chief HR Officer | MIXED | +4,094 | −$143.03K |
| 2026-07-29 | Michelle Quinn | EVP, GC and Secretary | F | −2,069 | −$179.75K |
| 2026-07-09 | Matthew R. Walter | SVP, Chief HR Officer | Sell | −3,102 | −$257.93K |
| 2026-06-09 | Harry Skip Kiil | EVP & President Cardiovascular | Sell | −4,189 | −$336.97K |
| 2026-06-08 | Harry Skip Kiil | EVP & President Cardiovascular | F | −6,817 | −$567.99K |
| 2026-06-08 | Michael Marinaro | EVP, Pres MedSurg and Americas | F | −7,471 | −$622.48K |
| 2026-06-08 | Denise L. Blomquist | Chief Accounting Officer | F | −237 | −$19.75K |
| 2026-06-08 | Matthew R. Walter | SVP, Chief HR Officer | F | −2,840 | −$236.63K |
| 2026-06-08 | Geoffrey Martha | Chairman and CEO | F | −41,936 | −$3.49M |
| 2026-05-28 | Denise L. Blomquist | Chief Accounting Officer | M | +1,712 | — |
| 2026-05-28 | Harry Skip Kiil | EVP & President Cardiovascular | M | +15,195 | — |
| 2026-05-28 | Michael Marinaro | EVP, Pres MedSurg and Americas | M | +18,994 | — |
| 2026-05-28 | Geoffrey Martha | Chairman and CEO | M | +94,963 | — |
| 2026-05-28 | Brett A. Wall | EVP & Pres Neuroscience | M | +26,907 | — |
| 2026-05-28 | Matthew R. Walter | SVP, Chief HR Officer | M | +9,149 | — |
| 2026-05-04 | Matthew R. Walter | SVP, Chief HR Officer | F | −35 | −$2.80K |
| 2026-04-29 | Craig Arnold | Director | MIXED | +1,904 | −$16.95K |
| 2026-04-29 | Scott C Donnelly | Director | MIXED | +1,904 | −$16.95K |
| 2026-04-29 | Lidia Fonseca | Director | MIXED | +1,904 | −$16.95K |
| 2026-04-29 | John P Groetelaars | Director | A | +1,444 | — |
| 2026-04-29 | Randall J Hogan | Director | MIXED | +1,904 | −$16.95K |
| 2026-04-29 | William R Jellison | Director | A | +1,444 | — |
| 2026-04-29 | Joon Sup Lee | Director | A | +1,803 | — |
| 2026-04-29 | Gregory P Lewis | Director | MIXED | +1,904 | −$16.95K |
| 2026-04-29 | Kevin E Lofton | Director | MIXED | +1,904 | −$16.95K |
| 2026-04-29 | Elizabeth G Nabel | Director | MIXED | +1,904 | −$16.95K |
| 2026-04-29 | Kendall J Powell | Director | MIXED | +1,904 | −$16.95K |
| 2026-04-29 | Denise L. Blomquist | Chief Accounting Officer | MIXED | +1,190 | −$26.04K |
| 2026-03-05 | Thierry Pieton | EVP & Chief Financial Officer | F | −2,976 | −$287.81K |
| 2026-02-26 | Harry Skip Kiil | EVP & President Cardiovascular | MIXED | −1,648 | −$507.71K |
| 2026-02-24 | Denise L. Blomquist | Chief Accounting Officer | G | −340 | — |
| 2026-02-02 | Denise L. Blomquist | Chief Accounting Officer | F | −148 | −$14.95K |
| 2025-12-17 | Geoffrey Martha | Chairman and CEO | F | −1,564 | −$156.20K |
| 2025-12-17 | Michael Marinaro | EVP, Pres MedSurg and Americas | F | −1,371 | −$136.92K |
| 2025-12-17 | Brett A. Wall | EVP & Pres Neuroscience | F | −439 | −$43.84K |
| 2025-12-09 | Harry Skip Kiil | EVP & President Cardiovascular | F | −1,702 | −$172.51K |
| 2025-11-24 | Denise L. Blomquist | Chief Accounting Officer | G | −170 | — |
| 2025-11-21 | Gregory L Smith | EVP Global Ops & Supply Chain | Sell | −30,000 | −$3.06M |
| 2025-09-05 | Harry Skip Kiil | EVP & President Cardiovascular | Sell | −8,605 | −$788.05K |
| 2025-08-25 | William R Jellison | Director | Buy | +5,000 | +$462.75K |
MDT — Current Insider Holders
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Geoffrey Martha | Chairman and CEO | 286,333 | $24.73M |
| Michael Marinaro | EVP, Pres MedSurg and Americas | 116,336 | $10.05M |
| Randall J Hogan | Director | 86,003 | $7.43M |
| Brett A. Wall | EVP & Pres Neuroscience | 82,183 | $7.10M |
| Sean Salmon | EVP & President Cardiovascular | 64,722 | $5.59M |
| Ivan K Fong | EVP GENERAL COUNSEL & SECR | 54,692 | $4.72M |
| Kendall J Powell | Director | 54,587 | $4.72M |
| Thierry Pieton | EVP & Chief Financial Officer | 49,645 | $4.29M |
| Gregory L Smith | EVP Global Ops & Supply Chain | 46,016 | $3.97M |
| Gary Louis Corona | Interim CFO | 44,255 | $3.82M |
| Harry Skip Kiil | EVP & President Cardiovascular | 42,186 | $3.64M |
| Craig Arnold | Director | 42,185 | $3.64M |
| Kweli Thompson | EVP & President, Neuroscience | 35,390 | $3.06M |
| Matthew R. Walter | SVP, Chief HR Officer | 34,159 | $2.95M |
| Jennifer M Kirk | Chief Accounting Officer | 28,011 | $2.42M |
| Michelle Quinn | EVP, GC and Secretary | 26,721 | $2.31M |
| Scott C Donnelly | Director | 24,131 | $2.08M |
| Elizabeth G Nabel | Director | 19,584 | $1.69M |
| Denise L. Blomquist | Chief Accounting Officer | 16,398 | $1.42M |
| Andrea Jo Goldsmith | Director | 10,463 | $903.79K |
| Kevin E Lofton | Director | 10,347 | $893.77K |
| Lidia Fonseca | Director | 7,851 | $678.17K |
| William R Jellison | Director | 6,444 | $556.63K |
| Gregory P Lewis | Director | 5,754 | $497.03K |
| Joon Sup Lee | Director | 1,803 | $155.74K |
MDT Insider Trading FAQ
Who are the insiders at MDT?
25 officers, directors and 10%+ beneficial owners currently report holdings in MDT via SEC Form 4.
Are MDT insiders buying or selling?
Across the 50 most recent Form 4 filings for MDT, 1 were open-market purchases (code P) and 5 were sales (code S). Sales frequently reflect scheduled 10b5-1 plans or tax withholding rather than a view on the stock.
How current is MDT insider data?
Form 4 must be filed within two business days of the transaction, so this is close to real time. The most recent MDT filing is dated 2026-09-17.
How to read Form 4 activity
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the MDT quote page; the site-wide leaderboard is on the insider transactions hub.
More on MDT
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.